TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3888169

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg plus scopolamine 0.4 mg with d-amphetamine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: scopolamine 1 mg with d-amphetamine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: scopolamine 0.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: scopolamine 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: scopolamine 0.6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: marezine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: meclizine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: dimenhydrinate 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: scopolamine 1 mg with d-amphetamine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: promethazine 25 mg with d-amphetamine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: scopolamine 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: scopolamine 0.8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg oral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg I.M.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg with scopolamine 0.4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg oral plus 25 mg I.M. with d-amphetamine 10 mg
Number of subjects: 0
Study: 30676814

Group type: EXPERIMENTAL
Intervention: 6.4% glucose (GLU)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6.4% maltose (MAL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin (MDX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 29112459

Group type: EXPERIMENTAL
Intervention: Atomoxetine + Parent Training (PT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Atomoxetine alone
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Parent Training (PT) alone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (PBO) alone
Number of subjects: 128
Study: 27761693

Group type: EXPERIMENTAL
Intervention: Curcuma longa extract
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 24943480

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP) 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22768457

Group type: EXPERIMENTAL
Intervention: Gonadotropin therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Laparoscopic ovarian electrocauterization
Number of subjects: 104
Study: 20880898

Group type: EXPERIMENTAL
Intervention: Combined β blocker and behavioural migraine management
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: β blocker alone
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Behavioural migraine management alone
Number of subjects: 232

Group type: COMPARATOR
Intervention: Optimised acute treatment alone
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Optimised acute treatment plus combined β blocker and behavioural migraine management
Number of subjects: 232
Study: 17581292

Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6MW)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: shuttle walking test (SWT)
Number of subjects: 23
Study: 15530671

Group type: EXPERIMENTAL
Intervention: PncCRM vaccine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control vaccine (hepatitis B)
Number of subjects: 115
Study: 11255809

Group type: EXPERIMENTAL
Intervention: Actinomycin D (one course administered within one week after evacuation of molar tissues)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (intravenous fluid and analgesic drugs only)
Number of subjects: 60
Study: 9825577

Group type: EXPERIMENTAL
Intervention: PE-C (ProME(Epidoxorubicin)CE‐CytaBOM)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PI-C (ProMI(Idarubicin)CE‐CytaBOM)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PE-C
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PI-C
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Consolidation therapy (after achieving complete remission)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Observation (no further therapy after complete remission)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Fatal toxicities
Number of subjects: 250
Study: 7647347

Group type: EXPERIMENTAL
Intervention: Psycho-social family intervention based on Expressed Emotion (EE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2469953

Group type: EXPERIMENTAL
Intervention: sulfomucopolysaccharide
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 333506

Group type: EXPERIMENTAL
Intervention: Amipaque
Number of subjects: 39

Group type: COMPARATOR
Intervention: Isopaque Coronar
Number of subjects: 39
Study: 31841780

Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Peer-led Body Project
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: eBody Project
Number of subjects: 680

Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 680
Study: 28277423

Group type: EXPERIMENTAL
Intervention: In-water training program with increased resistance (water parachute)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (same training without parachute)
Number of subjects: 12
Study: 29510398

Group type: EXPERIMENTAL
Intervention: Intravenous Diacetylmorphine (DAM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 28
Study: 26086587

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 0
Study: 23600965

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Combined treatment (physiotherapy + acupuncture)
Number of subjects: 120
Study: 22005660

Group type: EXPERIMENTAL
Intervention: 4 × 15 mL of 0.25% bupivacaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 19858328

Group type: EXPERIMENTAL
Intervention: Planning intervention including action and coping plans with two booster sessions
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 182
Study: 15703510

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 8725

Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 8725
Study: 11908844

Group type: EXPERIMENTAL
Intervention: Nondepressed participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subclinically depressed participants
Number of subjects: 0
Study: 10431945

Group type: EXPERIMENTAL
Intervention: Thermal vascular test (TVT)
Number of subjects: 199
Study: 7473523

Group type: EXPERIMENTAL
Intervention: Shared care
Number of subjects: 554

Group type: COMPARATOR
Intervention: Outpatient clinic (control)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Nurse-practitioner clinic (control)
Number of subjects: 554
Study: 2246657

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (maximal dose 24 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (administered for a minimum of six months at optimal dose)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyproheptadine therapy
Number of subjects: 7
Study: 7394143

Group type: EXPERIMENTAL
Intervention: Special Intervention group (received repeated reminders of risk and procedures for cessation of smoking, reduction of blood pressure, and dietary alteration to lower serum cholesterol)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Special Intervention group
Number of subjects: 575

Group type: COMPARATOR
Intervention: Usual Care group (received usual medical care as they saw fit)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 575
Study: 31479159

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: POLE-mutated CRCs
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: POLE status assessment
Number of subjects: 63
Study: 30784638

Group type: EXPERIMENTAL
Intervention: Active case finding strategy (combination of active and passive case finding)
Number of subjects: 25677

Group type: COMPARATOR
Intervention: Usual care (passive case finding)
Number of subjects: 25677
Study: 24754313

Group type: EXPERIMENTAL
Intervention: Eprotirome 100 μg day(-1)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Eprotirome 200 μg day(-1)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 23891459

Group type: EXPERIMENTAL
Intervention: Group motivational interviewing intervention (Free Talk)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 193
Study: 21312304

Group type: EXPERIMENTAL
Intervention: Testofen (600 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Testofen
Number of subjects: 60
Study: 19406557

Group type: EXPERIMENTAL
Intervention: Intravenous iron (two doses of 200mg iron sucrose)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Intravenous iron (three doses of 200mg iron sucrose)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Oral iron (daily 80 mg ferrous sulphate)
Number of subjects: 260
Study: 17579165

Group type: EXPERIMENTAL
Intervention: CT-guided core needle biopsy
Number of subjects: 0
Study: 15015443

Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 106
Study: 12899196

Group type: EXPERIMENTAL
Intervention: High-stress participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-stress participants
Number of subjects: 0
Study: 9549575

Group type: EXPERIMENTAL
Intervention: Aspirin 1.2 g daily in 3 divided doses from 2 days before to 14 days after surgery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran 500 ml, infused intravenously at 50 ml/hour during surgery and on each of the following 2 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 150
Study: 8056005

Group type: EXPERIMENTAL
Intervention: Nifedipine (specific dosage not mentioned)
Number of subjects: 348
Study: 2494249

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray, 400 micrograms daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Astemizole, 10 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Beclomethasone plus astemizole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Astemizole alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both trial medications (beclomethasone and astemizole)
Number of subjects: 90
Study: 29912983

Group type: EXPERIMENTAL
Intervention: 0.5 mg fast-release melatonin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 28731485

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) in the continuous blood purification (CBP) group, n = 11
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conventional comprehensive treatment plus high-volume hemofiltration (CBP group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional comprehensive treatment only (non-CBP group), n = 11
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline Th17%, Treg%, Th17/Treg, IL‐6, IL‐17, IL‐23, IL‐10 and TGF‐β1 in non-survival group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Th17% and Th17/Treg
Number of subjects: 48
Study: 26044463

Group type: EXPERIMENTAL
Intervention: FAmily CEntered advance care planning intervention (two face-to-face sessions with a trained facilitator: Session 1: Disease-Specific Advance Care Planning Respecting Choices Interview; Session 2: Completion of advance directive)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Healthy Living Control (two sessions: Session 1: Developmental/Relationship History; Session 2: Nutrition)
Number of subjects: 288
Study: 22171668

Group type: EXPERIMENTAL
Intervention: Self-tapping implants placed after bone condensing
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Non-self-tapping implants placed after bone condensing
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Self-tapping implants placed after bone drilling
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-self-tapping implants placed after bone drilling
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both implant types placed after bone condensing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both implant types placed after bone drilling
Number of subjects: 102
Study: 20873697

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine ophthalmic solution
Number of subjects: 47

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study: 18566549

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract, administered daily to once a week after six weeks.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as SLIT.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract
Number of subjects: 61
Study: 16641354

Group type: EXPERIMENTAL
Intervention: 3.0-T MR imaging
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1.5-T MR imaging
Number of subjects: 48
Study: 12918150

Group type: EXPERIMENTAL
Intervention: Oral Tegafur plus intravesical mitomycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravesical mitomycin alone
Number of subjects: 80
Study: 10463903

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8600872

Group type: EXPERIMENTAL
Intervention: Experimental seat (TCS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard cushions (control)
Number of subjects: 47
Study: 1752150

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with delayed gastric emptying (GET)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Diabetes mellitus patients with normal GET
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with delayed GET
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients
Number of subjects: 31
Study: 6890537

Group type: EXPERIMENTAL
Intervention: Intradermal BCG
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Antigen F (soluble cytoplasmic components of M. tuberculosis, M. aquae, and M. lepraemurium)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Antigen G (soluble cytoplasmic components of M. piscium and M. balnei)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Antigen H (soluble cytoplasmic components of M. leprae)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 31519504

Group type: EXPERIMENTAL
Intervention: Distractive video during local anesthetic administration
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no distractive video)
Number of subjects: 115
Study: 28647677

Group type: EXPERIMENTAL
Intervention: Buprenorphine (2–4 mg; sublingual)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (tablets with identical shape, color, consistency, and scent)
Number of subjects: 43
Study: 26395873

Group type: EXPERIMENTAL
Intervention: Motherhood decision aid (DA)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 23717406

Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention (patient education, support at the hospital, improved communication between treating and occupational physicians, and organizing a meeting for a gradual return-to-work plan)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 133
Study: 21343153

Group type: EXPERIMENTAL
Intervention: Fast track (FT) care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional care (TC)
Number of subjects: 99
Study: 19139383

Group type: EXPERIMENTAL
Intervention: Rifalazil 25 mg once weekly for 8 weeks
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Rifalazil
Number of subjects: 297

Group type: COMPARATOR
Intervention: Rifalazil and Placebo
Number of subjects: 297
Study: 18007568

Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 14964587

Group type: EXPERIMENTAL
Intervention: Diathermy and stretch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham diathermy and stretch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 11755953

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin administered 12 hours before and 12 hours after surgery, then once daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 11051950

Group type: EXPERIMENTAL
Intervention: Palliative care education project for nursing home staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participating nursing homes
Number of subjects: 0
Study: 9510925

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate supplementation for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 100
Study: 8457049

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.8 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 250
Study: 3086024

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 51Cr‐labelled ethylenediaminetetra‐acetate (51Cr‐EDTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L‐rhamnose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyethyleneglycol 400 (PEG‐400)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetrimide and hyperosmolar stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperosmolar stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactulose and 51Cr‐EDTA
Number of subjects: 0
Study: 29240023

Group type: EXPERIMENTAL
Intervention: Cathode tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Anode tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study: 27716690

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg loading dose over 15 min, maintained at 0.3 μg/kg/h)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 150
Study: 24249435

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, 28 days on and 14 days off)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sunitinib (post-placebo progression)
Number of subjects: 54
Study: 22447964

Group type: EXPERIMENTAL
Intervention: Biomarker-directed therapy (prednisolone or matching placebo based on blood eosinophil count)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard therapy (prednisolone for 2 weeks)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo in biomarker-negative exacerbations
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Prednisolone in biomarker-negative exacerbations
Number of subjects: 166
Study: 21083889

Group type: EXPERIMENTAL
Intervention: golimumab, 100 mg plus placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: golimumab, 50 mg plus MTX
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: golimumab, 100 mg plus MTX
Number of subjects: 336

Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 336
Study: 18771050

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha2b (1.0 microg/kg/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Recombinant interferon-alpha2b (3 million IU three times/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Number of subjects: 93
Study: 15645383

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB) with 20 ml bupivacaine 0.5 % + 60 ml prilocaine 1 %
Number of subjects: 99

Group type: COMPARATOR
Intervention: Epidural anaesthesia (EA) with 12 ‐ 20 ml bupivacaine 0.5 %
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PNB
Number of subjects: 99

Group type: COMPARATOR
Intervention: EA
Number of subjects: 99
Study: 12020336

Group type: EXPERIMENTAL
Intervention: Therapeutic shoes with customized medium-density cork inserts (n = 121)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Therapeutic shoes with prefabricated, tapered polyurethane inserts (n = 119)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual footwear (controls; n = 160)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Therapeutic shoes (both insert types)
Number of subjects: 400
Study: 10537441

Group type: EXPERIMENTAL
Intervention: Lamivudine added to zidovudine-containing regimens for 1 year
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Lamivudine added to zidovudine-containing regimens
Number of subjects: 1840
Study: 8620704

Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (IG) 60 mg qid for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (IG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (IG) and Placebo
Number of subjects: 26
Study: 2013587

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (5000 international units once daily)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard heparin (5000 international units three times a day)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 136